Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (0388.HK) [2] Core Insights - The company achieved a record high in performance for 2025, with total revenue and other income reaching HKD 29.16 billion, a year-on-year increase of 30%, and net profit attributable to shareholders amounting to HKD 17.75 billion, up 36% year-on-year [7] - The strong performance is attributed to increased trading and settlement fees due to record average daily trading (ADT) in the cash and derivatives markets, as well as robust growth in the Hong Kong IPO market, which led to a significant rise in listing fees [7] - The report forecasts continued revenue growth, with projected total revenues of HKD 29.63 billion in 2026, HKD 30.34 billion in 2027, and HKD 31.15 billion in 2028, reflecting growth rates of 1.6%, 2.4%, and 2.7% respectively [2][8] Financial Performance Summary - For 2025, the company reported: - Total revenue of HKD 29,161 million, with a growth rate of 30.3% - Net profit attributable to shareholders of HKD 17,754 million, with a growth rate of 36.0% - Earnings per share (EPS) of HKD 14.00, with a projected PE ratio of 30 [2][8] - The breakdown of revenue sources includes: - Trading and transaction system fees: HKD 10.33 billion, up 44% - Settlement and clearing fees: HKD 7.04 billion, up 49% - Listing fees: HKD 1.79 billion, up 21% - Investment income: HKD 5.11 billion, up 4% [7][8] Market Performance - The report highlights that the Hong Kong stock market's trading activity has improved significantly, which is expected to sustain the company's revenue growth [7] - The average daily trading volume in the cash market reached HKD 249.8 billion, a 90% increase year-on-year, with northbound trading ADT at HKD 212.4 billion, up 42%, and southbound trading ADT at HKD 121.1 billion, up 151% [7] - The IPO market saw 118 companies listed on the main board, raising HKD 286.8 billion, a 227% increase year-on-year [7]

Investment Rating - The report indicates a "Sell" rating for WuXi Biologics (2269 HK) due to a sell-off driven by fund flows rather than fundamentals [1]. Core Insights - The recent sell-off in WuXi Biologics and its subsidiary WuXi XDC, which saw declines of approximately 7% and 8% respectively, is attributed to position adjustments and fund flows rather than fundamental issues [1]. - The report highlights three key factors influencing the recent sell-off: strong performance year-to-date, the typical quiet period leading to profit-taking, and the spillover effects from U.S. CRO companies facing pressure due to AI-related concerns [4]. - The next potential catalyst for the stock is the official guidance for the fiscal year 2026, expected to clarify fundamentals such as order trends, pricing, capacity utilization, and overseas demand signals [4]. Summary by Sections Catalysts - The project momentum led by bispecific/multispecific drugs is expected to drive a re-acceleration of revenue growth in 2026 [3]. - The number of new projects in 2025 exceeded expectations with a net increase of 128 projects, laying the groundwork for faster growth in 2026 compared to 2025 [3]. - The geopolitical valuation discount is anticipated to diminish, with the impact expected to be less in 2026 than in 2024-2025 [3]. Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions to help partners develop biologics from concept to commercialization [6]. - Revenue breakdown shows that 88.8% comes from biologics and 11.2% from WuXi XDC, with geographical revenue distribution being 47.4% from the Americas, 30.2% from Europe, and 22.4% from Asia [7]. Market Information - As of February 25, 2026, the stock price is 41.36 HKD, with a market capitalization of 21.54 billion USD and a consensus target price of 43.85 HKD [10].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (0388.HK) with a target price of HKD 516.9 [2][9]. Core Insights - In 2025, Hong Kong Exchanges achieved a revenue of HKD 29.161 billion, representing a year-on-year increase of 30.3%, and a net profit attributable to shareholders of HKD 17.754 billion, up 36.0% year-on-year [2][10]. - The report highlights a significant increase in trading activity, with the average daily turnover in the cash market reaching HKD 249.8 billion, a 90% increase year-on-year, driven by renewed investor interest in Chinese assets and international capital inflow [3][4]. - The number of new listings in 2025 reached 119, an increase of 48 from the previous year, with total fundraising amounting to HKD 286.9 billion, a 227% increase year-on-year, positioning Hong Kong as a leading market for IPOs globally [4][9]. Summary by Sections Financial Performance - In Q4 2025, the company reported revenue of HKD 7.310 billion, a 14.6% increase year-on-year, and a net profit of HKD 4.335 billion, up 14.7% year-on-year [2]. - The revenue from the cash segment was HKD 14.704 billion, reflecting a 56.1% increase year-on-year, with trading fees and related services contributing significantly [3]. Market Activity - The report notes that the average daily turnover for the Stock Connect northbound and southbound trading increased by 42% and 151% respectively, indicating heightened market activity [3]. - The trading volume in the derivatives market also reached new highs, with an average daily contract volume of 1.6628 million contracts, a 7% increase from 2024 [9]. Revenue Structure - The revenue composition shows that trading and transaction system usage fees, along with settlement and custody fees, accounted for 64.7% of total revenue, an increase of 6.4 percentage points year-on-year [8]. - Investment income netted HKD 5.111 billion, a 3.7% increase year-on-year, with a notable rise in the scale of margin and settlement fund investments [9]. Future Outlook - The report anticipates continued growth in 2026, with projected earnings per share (EPS) of HKD 14.77, reflecting a strong market position and the potential for further capital inflow into Hong Kong [9][10]. - The company is expected to enhance its liquidity pool and market efficiency, focusing on developing a diversified asset ecosystem [9].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company achieved a revenue growth of 40% in 2025, marking its first year of profitability, with commercial success becoming evident [6][8]. - The primary revenue driver is the self-developed product, Zebutinib, which generated global sales of $28.1 billion, reflecting a year-over-year increase of 48.8% [8]. - The company provided guidance for 2026, expecting revenue between RMB 43.6 billion and RMB 45 billion, representing a year-over-year growth of 14% to 18% [8]. - Profit forecasts for 2026 to 2028 indicate net profits of RMB 2.47 billion, RMB 4.15 billion, and RMB 5.56 billion, with respective year-over-year growth rates of 73%, 68%, and 34% [8]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology sector, with a current H-share price of HKD 194.40 and a target price of HKD 229 [2][5]. Financial Performance - In 2025, the company reported total revenue of RMB 38.21 billion, a 40.4% increase year-over-year, with product revenue contributing RMB 37.77 billion [8]. - The net profit for 2025 was RMB 1.42 billion, a significant recovery from a net loss of RMB 4.98 billion in the previous year [8]. Earnings Forecast - The earnings per share (EPS) for 2026 is projected at RMB 2.4, with a price-to-earnings (P/E) ratio of 70 times [7][8]. - The company anticipates maintaining a high gross margin of around 80% in 2026 [8]. Market Position - The major shareholder is Amgen, holding 15.98% of the company [2]. - The stock has shown a year-over-year increase of 35.47% [2].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company achieved a revenue growth of 40% in 2025, marking its first year of profitability, with commercial success becoming evident [6][8]. - The primary revenue driver is the self-developed product, Zebutini (BTK inhibitor), which generated global sales of $28.1 billion, reflecting a year-over-year increase of 48.8% [8]. - The company provided guidance for 2026, expecting revenue between RMB 43.6 billion and RMB 45 billion, representing a year-over-year growth of 14% to 18% [8]. - Profit forecasts for 2026 to 2028 are adjusted to RMB 2.47 billion, RMB 4.15 billion, and RMB 5.56 billion, with respective year-over-year growth rates of 73%, 68%, and 34% [8]. Financial Summary - The company reported total revenue of RMB 38.21 billion for 2025, with product revenue contributing RMB 37.77 billion, a year-over-year increase of 39.9% [8]. - The net profit for 2025 was RMB 1.42 billion, a significant recovery from a net loss of RMB 4.98 billion in the previous year [8]. - The earnings per share (EPS) for 2025 is projected at RMB 1.40, with a forecasted increase to RMB 2.43 in 2026 [7][8]. - The company’s market capitalization is approximately RMB 171.82 billion, with a price-to-earnings (P/E) ratio of 121.42 for H shares in 2025 [2][7]. Market Performance - The stock price as of February 26, 2026, was HKD 194.40, with a target price set at HKD 229, indicating a potential upside [2][5]. - The stock has experienced a year-to-date increase of 35.47% [2].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 91.00, indicating a potential upside of 55.9% from the current price of HKD 58.35 [1][2][3]. Core Insights - The report highlights the sustained high activity in the global CXO sector, which is expected to benefit WuXi AppTec as industry demand improves. The company is projected to see over 20% growth in total orders from 2025 to 2027, with a significant increase in late-stage/commercial orders [2][6]. - The revenue and adjusted net profit forecasts for 2025-2027 have been slightly reduced by 1-3%, with expected revenues of RMB 58.79 billion, RMB 82.78 billion, and RMB 111.14 billion respectively, reflecting a strong CAGR of 38% to 46% driven by growth in comprehensive CMC orders [6][10]. - The report emphasizes WuXi AppTec's leading position in the high-growth XDC CRDMO sector, making it a top pick in the CXO industry due to its attractive investment value [6][10]. Financial Summary - Revenue projections for WuXi AppTec are as follows: RMB 5,879 million for 2025, RMB 8,278 million for 2026, and RMB 11,114 million for 2027, with corresponding adjusted net profits of RMB 1,600 million, RMB 2,454 million, and RMB 3,416 million [5][18]. - The gross profit margin is expected to remain stable at 35.1% for 2025, increasing to 39.1% by 2027, indicating improved profitability [5][20]. - The company's market capitalization is approximately HKD 73.4 billion, with an average daily trading volume of 8.31 million shares [5][6].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 91.00, indicating a potential upside of 55.9% from the current price of HKD 58.35 [1][2][3]. Core Views - The report highlights the sustained high activity in the global CXO sector, which is expected to benefit WuXi AppTec as industry demand improves. The company is projected to see over 20% growth in total orders from 2025 to 2027, with a significant increase in late-stage/commercial orders [2][6]. - The revenue and adjusted net profit forecasts for 2025-2027 have been slightly reduced by 1-3%, with expected revenues of RMB 58.79 billion, RMB 82.78 billion, and RMB 111.14 billion respectively, reflecting a strong CAGR of 38% to 46% during this period [6][10]. - The report emphasizes WuXi AppTec's leading position in the high-growth XDC CRDMO sector, suggesting that the current stock price offers high investment value at 0.6 times the 2026 PEG ratio [6][10]. Financial Summary - Revenue projections for WuXi AppTec are as follows: RMB 5,879 million for 2025, RMB 8,278 million for 2026, and RMB 11,114 million for 2027, with corresponding adjusted net profits of RMB 1,600 million, RMB 2,454 million, and RMB 3,416 million [5][18]. - The gross profit margin is expected to remain stable at 35.1% for 2025, increasing to 39.1% by 2027, indicating improved profitability [5][20]. - The company's market capitalization is approximately HKD 73.4 billion, with an average daily trading volume of 8.31 million shares [5][6].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - The company has adjusted its revenue growth guidance for the fiscal year 2026 to 8-12%, up from the previous estimate of 5-10%, indicating a positive outlook for revenue growth across various business lines [3][21]. - The company reported a significant increase in net revenue of $1.191 billion, representing a year-on-year growth of 14.7%, which exceeded market expectations [2][9]. - The Non-GAAP operating profit reached $89.13 million, showing a remarkable year-on-year increase of 206.9%, reflecting continuous improvement in profitability [2][9]. - Deferred revenue stood at $2.162 billion, marking a 10.2% year-on-year growth, which lays a solid foundation for future revenue recognition [2][9]. Revenue and Business Performance - The new education business remains the core growth driver, with a year-on-year revenue increase of 21.6%, benefiting from improved renewal rates [2][13]. - The number of active paid users for the smart learning system reached 352,000, reflecting a 34.9% year-on-year growth [2][13]. - The company has 1,379 teaching centers, with a cautious expansion strategy, increasing by 2% quarter-on-quarter [3][18]. Financial Projections - The company expects revenue growth of 11-14% for Q3 FY2026, with various segments projected to achieve accelerated growth [3][20]. - The forecast for net profit for the fiscal years 2026-2028 has been raised to $483 million, $555 million, and $620 million, respectively [4][21]. - The latest market capitalization corresponds to a price-to-earnings (PE) ratio of 19.5, 17.0, and 15.2 for the fiscal years 2026, 2027, and 2028 [4][21].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - The company has adjusted its revenue growth guidance for the fiscal year 2026, now expecting a growth rate of 8-12%, up from the previous estimate of 5-10% [4][20]. - The company reported a significant increase in net revenue for FY2026Q2, achieving $1.191 billion, which represents a year-on-year growth of 14.7%, exceeding market expectations [2][9]. - The Non-GAAP operating profit reached $89.13 million, marking a substantial increase of 206.9% year-on-year, indicating continuous improvement in profitability [2][9]. - Deferred revenue stood at $2.162 billion, reflecting a year-on-year growth of 10.2%, which lays a solid foundation for future revenue recognition [2][9]. Revenue and Business Performance - The new education business remains the core growth driver, with a year-on-year revenue increase of 21.6%, benefiting from improved renewal rates [2][13]. - The number of active paid users for the smart learning system reached 352,000, showing a year-on-year growth of 34.9% [2][13]. - The company has 1,379 teaching centers, reflecting a cautious expansion strategy with a 2% quarter-on-quarter increase [3][18]. - The adult and university student-related business saw a year-on-year revenue growth of 12.8%, although the growth rate slightly declined compared to the previous quarter [2][13]. Financial Projections - The company has revised its net profit forecasts for the fiscal years 2026-2028 to $480 million, $560 million, and $620 million, respectively, up from previous estimates [4][21]. - The latest market capitalization corresponds to a price-to-earnings (P/E) ratio of 19.5 for 2026, 17.0 for 2027, and 15.2 for 2028 [4][21]. - The expected revenue for FY2026 is projected to be $5.47 billion, with a year-on-year growth of 11.6% [5][23].

Group 1 - The investment rating for Galaxy Entertainment is maintained at OUTPERFORM with a target price of HKD 47.30 [2][6][17] - The company reported a net revenue of HKD 13.83 billion for Q4 2025, representing a year-on-year increase of 22.5% and a quarter-on-quarter increase of 13.7% [3][12][13] - Adjusted EBITDA reached HKD 4.3 billion, up 32.7% year-on-year, with an adjusted EBITDA margin of 31.1%, an increase of 2.4 percentage points year-on-year [3][5][15] Group 2 - The gaming revenue increased by nearly 30% year-on-year, significantly contributing to the overall growth of the company's earnings [4][13] - The company's market share improved to 21.8% in Q4 2025, up from 20.2% in Q3 2025 and 19.8% in Q4 2024 [5][16] - The forecast for net revenue for FY 2026 and 2027 is HKD 52.48 billion and HKD 56.71 billion, respectively, with expected growth rates of 6.6% and 8.1% [6][17]